Internal Medicine Department
Hematology Division

Guido J. Tricot, MD, PhD

Email:    guido.tricot@hsc.utah.edu

Education:

1983 – 1984    Ph.D., Katholieke Universiteit Leuven, Leuven, Belgium

1968 – 1975    M.D., Katholieke Universiteit Leuven, Leuven, Belgium

Training:

1978 – 1979    Fellow in Hematology/BMT, Leiden University Medical Center, Leiden, The Netherlands

1977 – 1978    Fellow, Katholieke Universiteit Leuven, Leuven, Belgium

1975 – 1977    Resident, Catharina Hospital, Eindhoven, The Netherlands

Other:

Director, Utah Blood/Marrow Transplant and Myeloma Program

Research Interests:

Multiple Myeloma
Lymphoma
Hodgkin's Disease

Selected Bibliography

  1. Barlogie B, Shaughnessy J, Bolejack V, Tricot G. (2006). The Thalidomide Confusion in Multiple Myeloma. (2006). Am J Hematol Oncol, 5:404-412.
  2. Zhan F, Huang Y, Colla S, Stewart J, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy J. (2006). The molecular classification of multiple myeloma. Blood, 108:2020-2028.
  3. Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J, Shaughnessy JD, Jagannath S, Bolejack V, Gurley J, Hoering A, Vesole D, Desikan R, Siegel D, Mehta J, Singhal S, Munshi NC, Dhodapkar M, Jenkins B, Attal M, Harousseau JL, Crowley J. (2006). Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol, 135(2):158-164.
  4. Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR, Hollmig K, Zangarri M, Pineda-Roman M, van Rhee F, Cavall F, Burington B, Crowley J, Tricot G, Barlogie B, Shaughnessy Jr JD. (2006). Frequent gain of chromosome band 1q21 in plasma cell dyscrasias detected by fluorescence in situ hybridization: Incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem cell transplantation. Blood, 108(5):1724-1732.
  5. Barlogie B, Tricot G, Rasmussen E, Anaissie E, van Rhee F, Zangari M, Fassas A, Hollmig K, Pineda-Roman M, Shaughnessy J, Epstein J, Crowley J. (2006). Total therapy 2 without thalidomide: comparison with total therapy 1: role of intensified induction and post-transplant consolidation therapies. Blood, 107(7):2633-2638.
  6. van Rhee F, Szmania SM, Zhan F, Gupta SK, Pomtree M, Lin P, Batchu RB, Moreno Spagnoli G, Shaughnessy J, Tricot GJ. (2005). NY-ESO-1 is highly expressed in poor prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood, 105(10):3939-3944.
  7. Zangari M, Barlogie B, Anaissie E, Saghafifar F, Eddlemon P, Jacobson J, Choon-Kee L, Thertulien R, Talamo G, Thomas T, van Rhee F, Fassas A, Fink L, Tricot G. (2004). Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. British Journal of Haematology, 126:715-721.
  8. Tricot G, Barlogie B, Van Rhee F. (2004). Treatment Advances in Multiple Myeloma. Br J Haematol, 125(1):24-30.
  9. Lee C, Zangari M, Barlogie B, Fassas A, van Rhee F, Thertulien R, Talamo G, Muwalla F, Anaissie E, Hollmig K, Tricot G. (2004). Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant, 33(8):823-828.
  10. Fassas AB, Barlogie B, Ward S, Jagannath S, Vesole D, Mattox S, Siegel D, Muwalla F, Zangari M, Anaissie E, Rhee FV, Thertulien R, Lee CK, Desikan R, Arzumanian V, McCoy J, Tricot G. (2003). Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience. Br J Haematol, 123(3): 484-489.
  11. Shaughnessy J, Barlogie B, Sawyer J, McCoy J, Fassas A, Zhan F, Bumm K, Epstein J, Anaissie E, Jagannath S, Vesole D, Siegel D, Desikan R, Munshi N, Badros A, Tian E, Zangari M. Jacobson J, Crowley J, Tricot G. (2003). Continuous absence of metaphase-defined cytogenetic abnormalities especially of chromosome 13 and hypodiploidy assures long-term survival in multiple myeloma treated with total therapy I: interpretation in the context of global gene expression. Blood, 101(10):3849-3856.
  12. Lee C, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J, van Rhee F, Cottler-Fox M, Muwalla F, Tricot G. (2003). DTPACE, an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol, 21(14):2732-2739.
  13. Lee CK, Badros A, Barlogie B, Morris C, Zangari M, Fassas A, van Rhee F, Cottler-Fox M, Jacobson J, Thertulien R, Muwalla F, Mazher S, Anaissie E, Tricot G. (2003). Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol, 31:73-80.
  14. Fassas AB, Spencer T, Sawyer J, Zangari M, Lee CK, Anaissie E, Morris C, Barlogie B, Tricot G. (2002). Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol, 118(4):1041-1047.
  15. Tricot G, Spencer T, Spoon D, Sawyer J, Desikan R, Fassas A, Badros A, Zangari M, Munshi N, Anaissie E, Toor A, Barlogie B. (2001). Predicting long term (> event-free survival in multiple myeloma patients following tandem autotransplants). Br J Haematol, 116:211-217.
  16. Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M, Desikan R, Shaver M, Fassas, A, McConnell S, Muwalla F, Barris Y, Anaissie E, Munshi N, Tricot G. (2001). Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol, 114:822-829.
  17. Zangari M, Anaissie E, Badros A, Desikan R, Gopal A, Morris C, Toor A, Siegel E, Fink L, Barlogie B, Tricot G. (2001). Increased risk of deep vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood, 98:1614-1615.
  18. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, Badros A, Zangari M, Anaissie E, Epstein J, Shaughnessy J, Ayers D, Spoon D, Tricot G. (2001). Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood, 98:492-494.
  19. Badros A, Barlogie B, Siegel E, Morris C, Desikan R, Zangari M, Fassas A, Anaissie E, Munshi N, Tricot G. (2001). Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol, 114: 600-607.
  20. Tricot G. (2000). New insights into role of microenvironment in multiple myeloma. Lancet, 355:248-250.
  21. Tricot G, Sawyer J, Jagannath S, Desikan KR, Siegel D, Naucke S, Mattox S, Barcy D, Munshi N, Barlogie B. (1997). The unique role of cytogenetics in the prognosis of patients with myeloma receiving high dose therapy and autotransplants. J Clin Oncol, 15:2659-2666.
  22. Tricot G, Gazitt Y, Leemhuis T, Jagannath S, Desikan KR, Siegel D, Fassas A, Tindle S, Nelson J, Juttner C, Tsukamoto A, Hallagan J, Atkinson K, Reading C, Hoffman R, Barlogie B. (1998). Collection, tumor contamination and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma. Blood, 91:4489-4495.
  23. Barlogie B, Jagannath S, Vesole D H, Naucke S, Cheson B, Mattox S, Bracy D, Salmon S, Jacobson J, Crowley J, and Tricot G. (1997). Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood, 89(3):789-793.
  24. Tricot G, Vesole D, Jagannath S, Hilton J, Munshi N, Barlogie B. (1996). Graft-versus-myeloma effect: Proof of principle. Blood, 87(3):1196-1198.
  25. Tricot G, Alberts D, Johnson C, Roe D, Dorr R, Bracy D, Vesole D, Jagannath S, Meyers R, Barlogie B. (1996). Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res, 2:947–952.
  26. Tricot G, Jagannath S, Vesole DH, Nelson J, Tindle S, Miller L, Cheson B, Crowley J, Barlogie B. (1995). Peripheral blood stem cell transplants for multiple myeloma--identification of favorable variables for rapid engraftment in 225 patients. Blood, 85(2):588–596.